H. Lundbeck AS - Company Profile
All the data and insights you need on H. Lundbeck AS in one report.
- Save hours of research time and resources with
our up-to-date H. Lundbeck AS Strategy Report
- Understand H. Lundbeck AS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company's products are indicated for the treatment of Alzheimer's disease, migraine, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, Italy, and France, and research centers in the US and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in Italy, China, Spain, Canada, France, South Korea, Australia, the US, and other countries. Lundbeck is headquartered in Valby, Denmark.
Determine H. Lundbeck AS go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.
Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for H. Lundbeck AS’s relevant decision makers and contact details.
Proactively evaluate H. Lundbeck AS’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
Identify which of H. Lundbeck AS’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
Understand H. Lundbeck AS’s commercialized product portfolio to stay one step ahead of the market.
Track drug and patent expiries along with geographies impacted.
Understand the current and future drug revenue for H. Lundbeck AS and assess market opportunity for new entrants with patient population 8-year forecasts.
Improve competitive bidding with insights into all publicly disclosed IT services contracts for H. Lundbeck AS (including IT outsourcing, business process outsourcing, systems integration & consulting and more).
Products and Services
|Lundbeck Institute – Educational Services
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
|In July, Lundbeck Export entered into a partnership with Bora Pharmaceuticals under which Bora will be responsible for sales and marketing of Lundbeck’s products through Bora’s specialized hospital, clinic, and drug store channels in Taiwan.
|In May, the company collaborated with Alloy Therapeutics for discovery of novel biologics therapies.
|In January, the company and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced that the U.S. Food and Drug Administration (FDA) determined that the supplementary New Drug Application (sNDA) for brexpiprazole.
|H. Lundbeck AS
|Novo Nordisk AS
|Orifarm Group A/S
|Leo Pharma AS
|United States of America
|No. of Employees
Key Financial Charts
|Lars Soren Rasmussen
|Charl van Zyl
|Chief Executive Officer; President
|Chief Financial Officer; Executive Vice President - Corporate Functions
|Executive Vice President; Chief Commercial Officer
|Non Dignissim Eros
|Non Dignissim Eros
|Non Dignissim Eros
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward